Expert Perspectives on the Latest Advancements in Breast Cancer

EP. 1: ESR Mutations and Resistance to Endocrine Therapy in Breast Cancer

June 23rd 2016

EP. 2: CDK4/6 Inhibitors in Hormone Receptor-Driven MBC

June 23rd 2016

EP. 3: FDA Breakthrough Status for Abemaciclib

June 23rd 2016

EP. 4: The Ongoing Role of Everolimus in ER-Positive MBC

June 23rd 2016

EP. 5: The Emerging Role of PI3K Inhibition in Breast Cancer

June 23rd 2016

EP. 6: What is New for HER2 MBC?

June 23rd 2016

EP. 7: Adjuvant TDM-1 and the KRISTINE Trial

June 23rd 2016

EP. 8: PHEREXA Trial in HER2+ Disease

June 23rd 2016

EP. 9: The Emerging Role of Neratinib in HER2+ MBC

June 23rd 2016

EP. 10: Patient Selection for Neratinib in Metastatic Breast Cancer

June 23rd 2016

EP. 11: Neratinib and HER2 Activating Mutations in Breast Cancer

June 23rd 2016

EP. 12: Biosimilar Trastuzumab in HER2-Positive Breast Cancer

June 23rd 2016

EP. 13: Is There a Role for TNBC Subtyping?

June 23rd 2016

EP. 14: Immunotherapy for TNBC

June 23rd 2016

EP. 15: Adjuvant Therapy for Breast Cancer

June 23rd 2016

EP. 16: AC versus TaxAC in High-Risk HER2-Negative MBC

June 23rd 2016

EP. 17: Practice-Changing Results from the MINDACT Trial

June 23rd 2016

EP. 18: Final Thoughts on Advanced Breast Cancer

June 23rd 2016

x